Full-Time

Patent Counsel

Confirmed live in the last 24 hours

Generation Bio

Generation Bio

51-200 employees

Develops durable genetic treatments for diseases

No salary listed

Senior

Cambridge, MA, USA

Category
Intellectual Property (IP)
Legal & Compliance
Requirements
  • JD. and bar admission in good standing in at least one state.
  • Registered to practice before the U.S. Patent and Trademark Office.
  • Advanced degree in organic chemistry, molecular biology, biochemistry, genetics or any other related fields.
  • Minimum of 6 years of experience post J.D., in a law firm and/or in-house pharmaceutical or biotechnology company practicing patent law, including management of complex global IP portfolios.
  • Excellent communication, negotiation, collaboration and interpersonal skills.
  • Client service focus and ability to adapt and prioritize.
Responsibilities
  • Prepare, file and prosecute U.S., and foreign patent applications in the fields of genetic medicine and organic chemistry.
  • Work closely with the research and development team to identify, evaluate, and file patent applications on new inventions, conduct prior art searches and IP landscape studies, manage new and existing patent portfolios.
  • Identify and manage the company’s trade secrets.
  • Proactively develop global intellectual property strategies for Generation Bio’s platform technologies in collaboration with business and scientific teams to ensure long-term competitive advantage.
  • Provide company scientists counseling on various legal issues including confidentiality and intellectual property.
  • Perform diligence with respect to patentability, validity, and freedom-to-operate.
  • Provide IP support for business development deals and partnership formation.
  • Support the company’s transactional team in drafting IP related agreements.
  • Review and oversee patent drafting and prosecution by outside counsel.
  • Manage outside counsel to maintain patent prosecution docket and rigorously implement IP strategies for US and foreign patent portfolios.
  • Strengthen and extend the company’s IP position.

Generation Bio focuses on developing genetic treatments for both rare and common diseases. Their main product is based on a non-viral genetic medicine platform that includes iqDNA, which is designed to be immune-quiet, and ctLNP, a delivery system that targets specific cells. This platform allows for the creation of treatments that can last for several years from a single dose and can be adjusted for dosage as needed. They use a unique manufacturing process called rapid enzymatic synthesis (RES) that enables them to produce large quantities of their genetic medicine efficiently. Unlike many competitors, Generation Bio aims to make these treatments accessible to a wider population by addressing significant medical needs with scalable solutions. Their goal is to provide durable and redosable genetic therapies that improve patient outcomes.

Company Size

51-200

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • Strategic reorganization extends cash runway into 2027, supporting R&D efforts.
  • Focus on both rare and prevalent diseases broadens market potential.
  • Moderna collaboration highlights demand for non-viral delivery systems.

What critics are saying

  • 40% workforce reduction may cause operational challenges and project delays.
  • Lease termination could indicate potential legal or financial disputes.
  • Reliance on collaboration income suggests potential financial instability.

What makes Generation Bio unique

  • Generation Bio's iqDNA evades immune detection, unlike traditional viral vectors.
  • Their ctLNP system targets specific cells, enhancing delivery precision.
  • RES manufacturing allows scalable production, meeting large-scale demand efficiently.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

-1%

2 year growth

3%
BioSpace
Feb 27th, 2025
Generation Bio To Present At The Td Cowen 45Th Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:10 a.m. ET in Boston. A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event

BioSpace
Apr 2nd, 2024
Generation Bio To Present At The 23Rd Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 at 12:45 p.m. ET.A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.About Generation BioGeneration Bio is innovating non-viral genetic medicines to provide durable and redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). With these platforms, Generation Bio aims to develop the next wave of non-viral genetic medicines to support its mission to extend the reach of genetic medicine to more people living with more diseases, around the world.For more information, please visit www.generationbio.com.Investors and Media Contact

TipRanks
Jan 31st, 2024
Generation Bio Co. Ends Lease Citing Landlord Breach

Generation Bio Co. ends lease citing landlord breach.

BioSpace
Nov 29th, 2023
Generation Bio Announces Strategic Reorganization To Extend Cash Runway For Development Of Ctlnp And Iqdna Platforms

Company to invest in highly selective cell-targeted lipid nanoparticle (ctLNP) delivery platform to develop wholly-owned programs for extrahepatic cell types. Development of immune-quiet DNA (iqDNA) platform for lead hemophilia A program to continueStrategic reorganization will result in a 40% reduction of workforce . Anticipated cost savings to extend cash runway into 2H 2027

Benzinga
Oct 18th, 2023
Generation Bio Announces Breakthrough In Its Non-Viral Genetic Medicine Platform With Novel "Immune-Quiet" Dna

Loading. Loading. Loading...– Immune-quiet DNA (iqDNA) is a novel variant of closed-ended DNA (ceDNA) that evades host innate immune detection in both mice and non-human primates (NHPs) with a systemic cytokine profile and tolerability comparable to mRNA– Company is advancing iqDNA in lieu of prior ceDNA constructs across all programs, including its lead program in hemophilia A– Company is extending cash runway guidance into 2026 through collaboration income and expense control while increasing investment in its iqDNA and cell-targeted lipid nanoparticle (ctLNP) platforms– Company will present data on iqDNA and ctLNP platforms at upcoming scientific meetings today and on October 26, and will host a webcast R&D event on November 1CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. GBIO, a biotechnology company developing genetic medicines for people living with rare and prevalent diseases, today announced the development of a proprietary, novel DNA called immune-quiet DNA (iqDNA). iqDNA is an optimized variant of the company's closed-ended DNA (ceDNA) that upon systemic administration with Generation Bio's lipid nanoparticle (LNP) delivery has shown cytokine levels and tolerability comparable to chemically modified messenger RNA (mRNA) in mice and non-human primates (NHPs).Generation Bio's non-viral genetic medicine platform aims to advance durable, redosable, and titratable therapies to reach potentially hundreds of millions of patients worldwide